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Purpose
Chemotherapy targets all rapidly growing cells, not only cancer cells, and thus is often 
associated with unpleasant side effects. Therefore, examination of the chemosensitivity
based on genotypes is needed in order to reduce the side effects. 
Materials and Methods
Various computational approaches have been proposed for predicting chemosensitivity
based on gene expression profiles. A linear regression model can be used to predict the 
response of cancer cells to chemotherapeutic drugs, based on genomic features of the
cells, and appropriate sample size for this method depends on the number of predictors.
We used principal component analysis and identified a combined gene expression profile
to reduce the number of predictors
Results
The coefficients of determinanation (R2) of prediction models with combined gene expres-
sion and several independent gene expressions were similar. Corresponding F values, which
represent model significances were improved by use of a combined gene expression profile,
indicating that the use of a combined gene expression profile is helpful in predicting drug
sensitivity. Even better, a prediction model can be used even with small samples because
of the reduced number of predictors. 
Conclusion
Combined gene expression analysis is expected to contribute to more personalized man-
agement of breast cancer cases by enabling more effective targeting of existing therapies.
This procedure for identifying a cell-type-specific gene expression profile can be extended
to other chemotherapeutic treatments and many other heterogeneous cancer types.
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Introduction
Breast cancer, the most common cancer in women, is a
major cause of female mortality. Approximately 232,340 new
cases of invasive breast cancer and 39,620 breast cancer
deaths were reported in the United States in 2013 [1-3]. In
Korea, breast cancer is the second most common cancer in
women, accounting for 19.8% of female cancer cases. 
Approximately 13,400 breast cancer cases were reported in
2009 and the rate of new diagnosis has been rising steadily
[4,5].
Treatment of breast cancer usually involves one or more
drugs, surgery, and sometimes radiation. Positive clinical 
responses to anticancer therapies are often restricted to a sub-
set of patients. Chemotherapy, a systematic drug regimen 
intended to stop cancer cells from dividing and growing, tar-
gets all rapidly growing cells, not only cancer cells, and is
therefore associated with unpleasant side effects [6]. Mutated
cancer genes contain biomarkers, making them good candi-
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dates for drug targeting [7]. Therefore, study of the relation-
ship between gene expression and drug sensitivity is requi-
red in order to administer the right drug to the right patient
and reduce the side effects of cancer treatment.
Scherf et al. [8] examined gene-gene, gene-drug, and drug-
drug interactions by combining gene expression data and
drug sensitivity data. The first limitation of their research
was that laboratory cell lines differ from tumor cells. Later,
Kao et al. [9] reported that gene expression patterns were
similar in their cell lines and primary breast cancer tumors.
Therefore, many studies for predicting chemosensitivity with
gene expression have used cell lines.
Several studies have demonstrated that genomic biomark-
ers can be used in prediction of chemotherapeutic responses
in human cancer patients [7,10-15]. Many such studies used
statistical methodologies or machine learning methods [10-
12].
The aim of this study was to predict drug sensitivity using
gene expression analysis and a linear regression model. The
necessary sample size for linear regression depends on the
number of predictive variables [16]. Sample size must 
increase as the number of predictors increases.
In this study, we suggest a method for implementing a
chemosensitivity prediction model with a reduced number
of predictors, which will be useful in cases with small sample
sizes. We identify a combined gene expression pattern that
requires fewer predictors than analysis involving several 
individual genes. Doxorubicin, an anthracycline widely used
in the treatment of breast cancer, was the targeted chemo-
therapeutic agent [17].
Materials and Methods
1. Data preparation
Two publicly available datasets of gene expressions and
drug sensitivities were used in this study. The first dataset
was compiled by Felding-Habermann et al. [18] for exami-
nation of gene expression in cell lines; it is accessible from a
public microarray database (gene expression omnibus
[GEO], GSE51086). This dataset consists of 29 cell lines, 
including 14 luminal, four basal A, and eight basal B cell lines
(the other three cell lines are of unknown type), and includes
45,220 probes, and it was summarized by 19,722 gene sym-
bols for this study. 
The other dataset, published by Garnett et al. [7], consists
of 608 cell lines and reports the IC50 scores of 111 drugs [10]
(inhibitory concentration, IC50, represents the concentration
of a drug required for 50% growth inhibition in vitro). Of
those, we looked at 43 breast cancer cell lines and 98 drugs,
because those missing more than 50% of data were excluded.
The datasets are summarized in Table 1.
2. Statistical methods
IC50 scores were standardized before performing statistical
analysis. Associations between gene expression and cell line,
drug sensitivity and cell line, and drug sensitivity and gene
expression in the combined dataset were examined. For this,
analysis of variance (ANOVA) was performed for identifica-
tion of significantly expressed genes among different types
of breast cancer cells. Correlation analysis was performed to
examine the relation of drug sensitivity to gene expression.
Linear regression was used for identification of a drug sen-
sitivity prediction model with gene expression as the predic-
tor.
3. DG-matrix analysis (the association of drug sensitivity
and gene expression)
The degree of similarity between the G-matrix (association
of gene expression and cell line) and D-matrix (association
of drug sensitivity and cell line) was calculated using the
Pearson correlation coefficient, r, calculated as follows:
, where xi denotes the gene expression of ith cell, yi denotes
r = ∑(xi –x ) 2 (yi –y ) 2
∑(xi –x ) (yi –y )
Table 1. Summary of the datasets used in this work
Data set No. of samples No. of probes
GSE51086 14 Lu, 4 BaA, 8 BaB, 3 unknown 45,220 probes (Agilent-014850  
(Dataset was published on (29 untreated breast cancer cell lines Whole Human Genome Microarray 4x44K),
Nov 27, 2013) vs. pool of all 29 cell lines) 19,722 gene symbol
Garnett et al. [7] 43 Breast cancer cell lines
(total 608 cell lines, 111 drugs)
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the IC50 of iih cell to drug y, x represents the average expres-
sion of gene x, and y represents the mean chemosensitivity
of drug y.
Principal component analysis (PCA) was used to reduce
the number of independent variables (the number of genes)
in the prediction model for drug sensitivity [19]. PCA is a
simple nonparametric statistical method that reduces data
dimensionality for conversion of correlated variables into 
uncorrelated variables, which are termed principal compo-
nents. Each principal component is represented in the form
of linear combinations of original variables. Therefore, a
value for each cell line can be calculated according to the fol-
lowing formula, which we call combined gene expression:
Combined gene expression=C1g1+C2g2+C3g3+… +Cngn
, where g1, g2, g3 … gn are gene expressions, and C1, C2, C3 …
Cn are weights of each gene expression.
In examining the association of gene expression and drug
sensitivity, cell lines which did not include gene expressions
or IC50 scores were excluded. The usage of datasets and a
schematic diagram of the study design are shown in Fig. 1.
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Fig. 1. The summary of the study plan using two published datasets. G-matrix includes 638 genes, which showed signifi-
cantly different expression among subtypes of breast cancer cell lines.
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Statistical analyses were performed using R ver. 3.1.1 (R
Foundation for Statistical Computing, Vienna, Austria), 
p < 0.05 was considered statistically significant. The PCA 
algorithm was also performed using R [20].
Results
1. Gene expression profiling of breast cancer cell lines 
(G-matrix)
The GSE51086 microarray dataset was used to examine the
relationship between gene expression and subtypes of breast
cancer cell lines. The dataset included 45,220 probes, and it
was summarized by 19,722 gene symbols for this study. The
three cell lines in the dataset that did not include subtype 
information were excluded. A total of 638 genes were iden-
tified by significance among breast cancer subtypes. The sub-
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Fig. 2. Expression patterns of 638 genes in breast cancer cell lines, identified by ANOVA. The vertical and horizontal axes
represent gene expressions and breast cancer cell lines, respectively.
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types of breast cancer cell lines were 14 luminal, four basal
A, and eight basal B. 
Unsupervised hierarchical clustering performed to exam-
ine the genetic characteristics of each cell line revealed sig-
nificant grouping of cell lines based on subtypes of breast
cancer (Fig. 2).
Orange color denotes low expression and yellow denotes
high expression. The gene expression pattern was clearly 
divided into several sections, which were strongly associated
with subtypes of breast cancer cell lines. Expression of the
first gene group was decreased in the order of basal A > basal
B > luminal, and expression of the second group was 
increased according to the same order (i.e., basal A < basal B
< luminal).
2. Chemosensitivity profiling of breast cancer cell lines 
(D-matrix)
The dataset from Garnett et al. [7] was used to examine the
chemosensitivity of breast cancer cell lines. The dataset orig-
inally included 111 drugs and 43 breast cancer cell lines;
however, cell lines and drugs with more than 50% missing
data were excluded. Thus, 98 drugs and 31 breast cancer cell
lines from this dataset were used in this study. The IC50
scores were standardized due to the large variation in the
scale of IC50 scores for different drugs.
When unsupervised hierarchical clustering was applied to
the dataset, there was no association between drug sensitiv-
ity and cell line (Fig. 3). 
Each column represents a cell line, and each row repre-
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Fig. 3. Patterns of standardized IC50 scores in 31 breast cancer cell lines. The vertical and horizontal axes represent 98 drugs
and 31 breast cancer cell lines, respectively.
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sents the IC50 score for the particular compound. Both rows
and columns are clustered hierarchically. Yellow color rep-
resents high IC50 score (resistant), orange color represents
low IC50 score (sensitive), and white indicates absence of
data.
As shown in Fig. 3, no clear relationship was observed 
between drug sensitivity and breast cancer cell line. The cell
lines CAL51 and MCF7 were sensitive to most drugs (orange
color represents low IC50 scores), compared to other cell lines.
By contrast, UACC812 was resistant to most drugs, though
it should be noted that there were several drugs which did
not include IC50 scores.
To examine the relationship between gene expression and
drug sensitivity in detail, we selected four drugs, mitomycin,
doxorubicin, gemstabine and obatoclax mesylate, all of
which have been used for the treatment of breast cancer. 
Unsupervised hierarchical clustering showed an associa-
tion between drug sensitivity and cell line (Fig. 4). 
The cell lines were divided into three groups by unsuper-
vised hierarchical clustering, which were independent of
breast cancer subtype, indicating that drug sensitivity is 
associated with specific gene expression rather than subtype
of breast cancer. 
Given this association pattern, doxorubicin was selected
as a specific drug for implementing the drug sensitivity pre-
diction model. Doxorubicin, which was discovered in 1969
by Farmitalia Research Laboratories in Italy, is used in treat-
ment of early-stage or node-positive breast cancer, HER2-
positive breast cancer, and metastatic disease. The first two
cell line groups were sensitive to doxorubicin while the third
was resistant, as shown in the tree diagram (Fig. 4).
3. Correlation between drug sensitivity and gene expres-
sion (DG-matrix)
For screening of the genes associated with chemosensitiv-
ity, the databases for gene expression and for chemosensitiv-
ity were integrated into one database matrix (DG-matrix)
using the Pearson correlation coefficient. Using the DG-
matrix, hierarchical clustering was performed based on the
correlation between drug sensitivity and gene expression
(Fig. 5).
Significantly expressed genes among subgroups of breast
cancer cell lines were used to examine the association of gene
expression and drug sensitivity. Several sectional blocks 
(indicated by orange and yellow) are shown in Fig. 5, sug-
gesting a relationship between gene expression and drug
sensitivity. The orange and yellow colors represent the neg-
ative and positive relationship between gene expression and
drug sensitivity, respectively. Therefore, it can be interpreted
that the drugs shown in the dashed box could be sensitive
when the genes shown in the box are overexpressed (nega-
tive relationship).
It also shows that the genes related to subtypes of breast
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Fig. 4. Patterns of standardized IC50 of four drugs in 31 breast cancer cell lines. The vertical and horizontal axes represent
four drugs and 31 breast cancer cell lines, respectively.
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cancer cell lines are also related to drug sensitivity. Therefore,
implementation of a drug sensitivity prediction model using
gene expression data is reasonable, as gene expression differs
between subtypes of breast cancer.
4. Selection of genes associated with drug-specific chemo-
sensitivity
Correlation coefficients and their significance of both gene
expression and IC50 scores in the four drugs were calculated.
Drug sensitivity-related genes were identified as having cor-
relation coefficients of |0.7| with drug-specific chemosen-
sitivity. The results are listed in Table 2. Fifteen genes
showed strong correlation with the IC50 score of each drug.
Genes showing strong correlation with specific drug sen-
sitivity for implementing the drug sensitivity prediction
model were selected. 
5. Drug sensitivity prediction model using gene expression
In implementing our prediction model for sensitivity to
doxorubicin, 10 genes were used as predictive variables. Five
genes showed positive correlation with drug sensitivity and
the other five genes showed negative correlation (Fig. 6). 
As shown in Fig. 6, doxorubicin-related genes showed
strong association with sensitivity to doxorubicin (|r|> 0.77,
p < 0.001) but were not associated with sensitivity to mito-
mycin (|r|< 0.45, p > 0.05). This result indicates that the drug
sensitivity model can be implemented for each specific drug
and the genes related to it.
The optimal prediction model was identified by backward
estimation in linear regression, and the final model included
PARVA, TBX21, SHF, and FAM158A as predictors. The 
expression data of the four genes were combined to reduce
the number of predictors. Combined gene expression was
calculated by PCA.
–0.5 0 0.5
Fig. 5. DG-matrix. Correlation pattern of 638 gene expressions and standardized IC50 scores of 98 drugs. The vertical and
horizontal axes represent 638 genes and 98 drugs, respectively. Correlation coefficients range from –1 to 1.
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We compared the significances of two models, one using
four independent genes and the other using the combined
gene expression (Table 3).
A combined biomarker was calculated by linear, weighted
combination of the four genes. The two models were similar
in p-value and R2, and the F value was significantly increased
when a combined biomarker was used. Hence, the combined
biomarker is reliable in our drug sensitivity prediction
model.
Sensitivity to doxorubicin was associated with up-regula-
tion of TBX21, SHF, and FAM159A. The combined factor
showed a strong negative association with doxorubicin IC50
score. These results indicate that the more up-regulated the
expression of these genes, the more sensitive the cells are to
doxorubicin. Different color points represent subtypes of
breast cancer cell lines. Breast cancer subtype was not found
to be a predictive factor in this study (Fig. 7).
Discussion
Development of a method to predict what drug will be
most effective in each case is needed in order to reduce the
unpleasant side effects of chemotherapy for breast cancer 
patients. We suggest a prediction method using combined
gene expression. This method is based on linear regression
with IC50 scores of doxorubicin as the response variable. A
statistical method was applied to reduce the number of pre-
dictors in the regression model so that the model is useful
even in a small dataset.
The number of predictive variables has a significant influ-
ence on sample size and statitical power [21]. As the number
of predictive variables is increased, the sample size must also
be increased. Therefore, PCA was applied to reduce the num-
ber of predictive variables by combining several predictors.
By combining gene expression profiling with drug sensi-
tivity data, we examined a large set of possible gene-drug 
relationships. These two datasets, which include gene expre-
ssion and drug sensitivity, were derived from the public
database (GEO database) and a previously published dataset
[8]. Previous results showed that breast cancer is comprised
of molecularly distinct subtypes that may respond differently
to targeted therapies [22]. However, in this study drug sen-
sitivity was related to gene expression rather than subtype
of breast cancer cell lines. 
Scherf et al. [8] reported that clustering of cell lines on the
basis of gene expression yielded relationships that were very
different from those obtained by clustering cell lines based
on their response to drugs. This is in accordance with our
study. However, a strong relationship was observed between
gene expression and drug sensitivity, indicating that drug
sensitivity can be predicted by gene expression data.
Mitomycin Doxorubicin Gemcitabine Obatoclax mesylate
Gene r Gene r Gene r Gene r
FAM149A 0.8089 LHFPL2 0.8043 IPW 0.8351 TAZ 0.7864
GLRB 0.7851 ARSB 0.8026 SNURF 0.8122 RHBDL2 0.75747
PRDM5 0.7739 GLRX 0.7797 NAGA 0.7867 YOD1 0.73705
PPAP2A 0.7611 GLRXL 0.7787 TNFAIP8L3 0.7519 KEL 0.7330
PXK 0.7369 PARVA 0.7556 COPS5 0.7476 LEMD2 0.7227
ZNF525 –0.7583 ACR –0.7751 NKRF –0.8465 FBXL19 –0.8170
SCN7A –0.7399 DARS2 –0.7712 UBL4A –0.8294 APOH –0.8033
PTPN4 –0.7359 TBX21 –0.7605 USP29 –0.7876 TSEN2 –0.7928
USP8 –0.7296 SHF –0.7571 CDH24 –0.7829 TUBD1 –0.7908
FTO –0.7291 FAM158A –0.7537 SPATA12 –0.7791 PFDN4 –0.7777
EPB41 –0.7233 RFC1 –0.7429 CC2D2B –0.7501 BCAS3 –0.7654
PPM1B –0.7217 KCTD15 –0.7333 KRT80 –0.7433 POU1F1 –0.7502
WDR33 –0.7214 PTP4A3 –0.7299 ANKRD39 –0.7423 CA4 –0.7419
AIFM1 –0.7182 MNX1 –0.7296 MFSD9 –0.7409 CTRB1 –0.7411
BCL2L11 –0.7089 KRT32 –0.7270 DXS542 –0.7388 GABPB1 –0.7316
The p-values of the genes were less than 0.001. The standardized IC50 scores were used for calculating correlation coefficients.
r represents correlation coefficient.
Table 2. List of the top-ranked genes which showed positive or negative association with drug-specific chemosensitivity
for four drugs
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Table 3. Comparison of model significances in cases using four individual genes and a combined gene expression
Drug Gene list in Model Weights of genes Model the model significance (combined biomarker) significance
Doxorubicin PARVA F=58.238a) –0.812 F=198.309
TBX21 p < 0.001b) 0.772 p < 0.001
SHF R2=0.939c) 0.614 R2=0.934
FAM158A 0.552
a)F value represents model statistics, model significance is improved as F value is increased, b)p < 0.05 is generally interpreted
as statistically significant, c)R2 ranged from 0 to 1. When this value is 1, the model is perfectly predictive.
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Fig. 7. Association of gene expressions and chemosensitivity to doxorubicin in breast cancer. Doxorubicin represents IC50
scores against doxorubicin and combined biomarker represents combined gene expression.
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Various statistical and computational methods have been
previously applied for prediction of IC50 scores [10-12]. When
the statistical method is used for predicting chemosensitivity,
sample size can be a very influential factor for achieving high
statistical power, and sample size depends on the number of
predictors in the linear regression method, which can be used
for predicting numeric dependent variables (e.g., IC50). 
Therefore, our aim in this study was not to suggest a novel
prediction method, but rather to show that the performance
of a prediction model can be improved by reducing the num-
ber of predictors. PCA was used to reduce the number of pre-
dictors and to identify a combined gene expression profile. 
The performance of the prediction model using combined
gene expression was better than that of the model using sev-
eral independent gene expressions. Model significance was
improved when combined gene expression was used as a
predictive variable.
The discovery of biomarkers of breast cancers has led to
development of treatment strategies for breast cancer 
patients. Identification of combined gene expression profiles
is expected to contribute to more personalized menagement
of breast cancer patients and to improve existing therapies
and it will be helpful in finding new therapies by identifying
more predictive biomarkers. It can also be extended to other
chemotherapeutic treatments and other cancer types.
Conclusion
The advantage of the proposed method is that the predic-
tion model can be implemented with a relatively small sam-
ple dataset by reducing the number of predictive variables.
A limitation of this study is that we did not consider the sub-
types of breast cancer cell lines in our prediction model. With
more available data, subtype of breast cancer should be con-
sidered as a predictive factor, even though it was not associ-
ated with drug sensitivity in this study. Our further study
will include the validation of the result using an independent
dataset and extension of the proposed method to other can-
cer types. 
Conflicts of Interest
Conflict of interest relevant to this article was not reported.
Acknowledgments
This study was supported by a faculty research grant of
Yonsei University College of Dentistry for 2015 (6-2015-0003).
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.
Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics,
2013. CA Cancer J Clin. 2014;64:52-62.
3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal
A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-
108.
4. Oh HS. Targeted therapy for breast cancer. Hanyang Med Rev.
2012;32:112-7.
5. Jung KW, Won YJ, Oh CM, Kong HJ, Cho H, Lee JK, et al. Pre-
diction of cancer incidence and mortality in Korea, 2016. Can-
cer Res Treat. 2016;48:451-7.
6. BreastCancerTrials.org [Internet]. San Francisco, CA: Breast-
CancerTrials.org; 2016 [cited 2016 May 1]. Available from:
https://www.breastcancertrials.org/.
7. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur
A, Lau KW, et al. Systematic identification of genomic markers
of drug sensitivity in cancer cells. Nature. 2012;483:570-5.
8. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L,
et al. A gene expression database for the molecular pharma-
cology of cancer. Nat Genet. 2000;24:236-44.
9. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, et
al. Molecular profiling of breast cancer cell lines defines rele-
vant tumor models and provides a resource for cancer gene
discovery. PLoS One. 2009;4:e6146.
10. Menden MP, Iorio F, Garnett M, McDermott U, Benes CH,
Ballester PJ, et al. Machine learning prediction of cancer cell
sensitivity to drugs based on genomic and chemical proper-
ties. PLoS One. 2013;8:e61318.
11. Ferriss JS, Kim Y, Duska L, Birrer M, Levine DA, Moskaluk C,
et al. Multi-gene expression predictors of single drug 
responses to adjuvant chemotherapy in ovarian carcinoma:
predicting platinum resistance. PLoS One. 2012;7:e30550.
12. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP,
Karpovich J, et al. A strategy for predicting the chemosensi-
tivity of human cancers and its application to drug discovery.
Proc Natl Acad Sci U S A. 2007;104:13086-91.
13. De Abreu FB, Schwartz GN, Wells WA, Tsongalis GJ. Person-
References
Xianglan Zhang, Drug Sensitivity Prediction Using Gene Expression Profiles
VOLUME 49 NUMBER 1 JANUARY 2017  127
alized therapy for breast cancer. Clin Genet. 2014;86:62-7.
14. Ring BZ, Chang S, Ring LW, Seitz RS, Ross DT. Gene expres-
sion patterns within cell lines are predictive of chemosensitiv-
ity. BMC Genomics. 2008;9:74.
15. Wu D, Pang Y, Wilkerson MD, Wang D, Hammerman PS, Liu
JS. Gene-expression data integration to squamous cell lung
cancer subtypes reveals drug sensitivity. Br J Cancer. 2013;
109:1599-608.
16. Knofczynski GT, Mundfrom D. Sample sizes when using mul-
tiple linear regression for prediction. Educ Psychol Meas.
2008;68:431-42.
17. Ku JM, Kim SR, Hong SH, Choi HS, Seo HS, Shin YC, et al.
Cucurbitacin D induces cell cycle arrest and apoptosis by 
inhibiting STAT3 and NF-kappaB signaling in doxorubicin-
resistant human breast carcinoma (MCF7/ADR) cells. Mol
Cell Biochem. 2015;409:33-43.
18. Felding-Habermann B, O’Sullivan DM, Lorger M, Mac-
Dermed D, Fernandez-Santidrian A, Steele JB, et al. PD03-07:
Breast cancer heterogeneity and treatment resistance: clues
from metaplastic tumors. In: Thirty-Fourth Annual CTRC-
AACR San Antonio Breast Cancer Symposium; 2011 Dec 6-10;
San Antonio, TX, USA.
19. Fukunaga K. Introduction to statistical pattern recognition.
Boston, MA: Academic Press; 1990.
20. R Foundation. The R Project for Statistical Computing [Inter-
net]. Vienna: R Foundation; 2016 [cited 2016 May 1]. Available
from: http://www.r-project.org/.
21. Cohen J. Statistical power analysis for the behavioral sciences.
2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
22. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC,
Ng S, et al. Subtype and pathway specific responses to anti-
cancer compounds in breast cancer. Proc Natl Acad Sci U S A.
2012;109:2724-9.
128 CANCER  RESEARCH  AND  TREATMENT
Cancer Res Treat. 2017;49(1):116-128
